Loading
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
Latest quote
$4.68
−$0.08 · -1.68%
After-hours
$4.68
$0.00 · 0.00%
Sep 16, 7:30 PM ET
Regular session · ET · Market data may be delayed.
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
Day range
Current $4.68
52-week range
Current $4.68
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
54
Mixed
Risk
82
Extreme Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
Day range
Current $4.68
52-week range
Current $4.68
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 856K USD | 1.31M USD | 2.88M USD | 1.35M USD | 1.07M USD |
| Cost of goods sold | 225K USD | 800K USD | 683K USD | 322K USD | 33K USD |
| Gross profit | 631K USD | 506K USD | 2.2M USD | 1.03M USD | 1.04M USD |
| Research and development | 2.19M USD | 1.82M USD | 1.64M USD | 2.8M USD | 1.99M USD |
| Selling, general, and administrative | 5.44M USD | 5.81M USD | 6.13M USD | 6.27M USD | 3.64M USD |
| Operating expenses | 9.38M USD | 7.82M USD | 7.97M USD | 8.41M USD | 5.77M USD |
| Interest income | 207K USD | 421K USD | — | 1.24M USD | 18K USD |
| Interest expense | 11K USD | 30K USD | 9K USD | 36K USD | 12K USD |
| Depreciation and amortization | 234K USD | 482K USD | 538K USD | 187K USD | 33K USD |
| Operating income | −8.75M USD | −7.32M USD | −5.77M USD | −7.38M USD | −5.77M USD |
| Net income | −12.18M USD | −6.28M USD | −5.12M USD | −2.59M USD | −5.8M USD |
Company facts updated Sep 17, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Avantis Emerging Markets Equity ETFAVEM1.11M—27.92B USD0.33%$92.42-0.13%
Avantis Emerging Markets Value ETFAVES187.53K0.01%1.55B USD0.36%$64.52-0.36%
Avantis Emerging Markets Small Cap Equity ETFAVEE110.12K0.08%134.43M USD0.42%$67.40+0.15%
Avantis Emerging Markets ex-China Equity ETFAVXC105.87K0.02%457.43M USD0.33%$81.0172-0.14%Avantis Emerging Markets Equity ETFAVEMAvantis Emerging Markets Value ETFAVESAvantis Emerging Markets Small Cap Equity ETFAVEEAvantis Emerging Markets ex-China Equity ETFAVXCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
